IDEAYA Biosciences Reports $8.9M Collaboration Revenue and $112.5M Net Loss in Q2 2026

IDEAYA Biosciences, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $8.9 million for the three months ended June 30, 2026, a significant increase from zero revenue in the same period last year. For the first half of 2026, total revenue reached $15.4 million, attributed entirely to the Servier License Agreement. Despite this revenue growth, the company incurred a net loss of $112.5 million for the quarter, compared to a loss of $77.5 million in the prior year, and a total net loss of $211 million for the first half of 2026, up from $149.7 million in the same period of 2025.

Operating expenses for the second quarter of 2026 totaled $131.1 million, a 48% increase from $88.8 million in the same quarter of 2025. This rise was driven primarily by a 46% increase in research and development expenses, which amounted to $108.7 million, reflecting the company's ongoing investment in its clinical programs. General and administrative expenses also rose by 54% to $22.5 million, largely due to increased personnel costs and consulting fees related to commercial preparation activities for its lead product candidates.

In terms of strategic developments, IDEAYA completed a follow-on public offering in June 2026, raising approximately $345 million in gross proceeds. The offering included 7,222,225 shares of common stock and pre-funded warrants, significantly bolstering the company's cash position. As of June 30, 2026, IDEAYA reported cash, cash equivalents, and marketable securities totaling approximately $1.24 billion, providing a solid financial foundation to support its ongoing clinical trials and operational needs.

The company has made notable progress in its clinical pipeline, particularly with darovasertib, which is being evaluated for uveal melanoma. IDEAYA is advancing multiple clinical trials, including a Phase 2/3 trial in combination with Pfizer's crizotinib, and plans to submit a new drug application to the FDA in the latter half of 2026. The company is also exploring additional collaborations and partnerships to enhance its product development capabilities.

Looking ahead, IDEAYA anticipates continued operating losses as it invests in the development of its product candidates. Management expects that the current cash reserves will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, including the need for additional financing to support its growth and development initiatives.